Overview

A Clinical Study of MK-1084 and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Status:
NOT_YET_RECRUITING

Trial end date:
2032-08-06

Target enrollment:

Participant gender:

Summary

Researchers want to learn if the study medicines MK-1084 and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. MK-1084 is a targeted therapy for the KRAS G12C mutation. The goal of this study is to learn if people who receive MK-1084 with SC pembrolizumab live longer without the cancer growing or spreading than in people who receive SC pembrolizumab with chemotherapy.

Phase:

PHASE3

Details

Lead Sponsor:

Merck Sharp & Dohme LLC

Treatments:

Carboplatin
Cisplatin
pembrolizumab
Pemetrexed